Long-Term Successful Virological Suppression with Dolutegravir Monotherapy in the EARL-SIMPLIFIED Trial

Scott, Jake MD

Clinical Assistant Professor, Infectious Diseases and Geographic Medicine, Stanford University School of Medicine; Antimicrobial Stewardship Program Medical Director, Stanford Health Care Tri-Valley

Infectious Disease Alert 42(11):p 124-126, August 2023.

SYNOPSIS: Dolutegravir monotherapy was demonstrated to be non-inferior as compared with combination antiretroviral therapy in EARLY-SIMPLIFIED, a randomized controlled trial with long-term follow-up that included a highly selected group of people with HIV-1 infection.

SOURCE: West E, Zeeb M, Grube C, et al. Sustained viral suppression with dolutegravir monotherapy over 192 weeks in patients starting combination antiretroviral therapy during primary HIV infection (EARLY-SIMPLIFIED): A randomized, controlled, multi-site, non-inferiority trial. Clin Infect Dis 2023; Jun 20;ciad366. doi: 10.1093/cid/ciad366. [Online ahead of print].